CITRIM 2017.

Methods	Study design: parallel RCT Study duration: July 2012 to July 2014 Duration of follow‐up: 180 days
Participants	Setting: single centre Country: Brazil Patients > 18 years; CKD or AKI requiring HD through a catheter; admitted to ICU Number (catheters): treatment group (233); control group (231) Mean age ± SD (years): Treatment group (58.61 ± 17.14); control group (57.44 ± 18.27) Sex (males): treatment group (50.21%); control group (47.82%) Exclusion criteria: patients with a tunnelled catheter; suspected heparin‐induced thrombocytopenia; allergy to heparin or trisodium citrate; systemic or localised infection; pregnant women
Interventions	Treatment group Trisodium citrate: 30% (Citra‐Lock™ 30 %, Fresenius MedicalCare). Control group Unfractionated sodium heparin: 5000 U/mL
Outcomes	CRI Catheter dysfunction
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"...computer‐generated list of random numbers in blocks of six."
Allocation concealment (selection bias)	Low risk	"...was performed using opaque, sealed envelopes"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Patients and investigators were unaware of the treatment assignments"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Low risk	Describes the outcome according to protocol
Other bias	Unclear risk	Funding source not reported